COVID-19 Clinical Trial
— COVID-TGTOfficial title:
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients: Thrombin Generation Potential in COVID-19 Infected Patients
Verified date | September 2022 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.
Status | Completed |
Enrollment | 175 |
Est. completion date | June 2, 2022 |
Est. primary completion date | February 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient with SARS-CoV-2 infection entering hospitalization with or without resuscitation - The patient (or their carer) must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: - Pregnant or breastfeeding patient - It is impossible to give the subject informed information - The patient is under safeguard of justice or state guardianship - Thrombotic events during treatment: flare-up of venous thromboembolism, flare-up of atherothrombosis. - Long-term anticoagulant treatment (anti-vitamin K, direct oral anticoagulant). - Chronic anti-aggregation treatment. - Pre-existing constitutive or acquired known coagulation pathology: hemorrhagic diseases (thrombocytopenia, thrombocytopathy, hemophilia, von Willebrand's disease, hemorrhagiparous factor deficiency), and for thrombophilia (deficits in antithrombin, protein C or S , Factor V Leiden or Prothrombin 20201A mutation). |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeaux | Bordeaux | |
France | CHU de Limoges | Limoges | |
France | CHU de Montpellier | Montpellier | |
France | CHU de Nimes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 28-day survival rate | Death yes/no during hopstilization, 28 days after admittence | 1 month | |
Primary | Absolute thrombin generation test latent period | Seconds; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test latent period compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Absolute thrombin generation test initial velocity | nmol/s; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test initial velocity compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test peak thrombin compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Absolute thrombin generation test peak thrombin | nmol/L; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Absolute thrombin generation test peak thrombin time | Seconds; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test peak thrombin time compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Absolute thrombin generation test total thrombin generation time | seconds; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test total thrombin generation time compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Absolute thrombin generation test endogenous thrombin potential | Seconds; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Primary | Relative thrombin generation test endogenous thrombin potential compared to reference plasma | %; without (TM-) and with (TM+) purified thrombomodulin | Day 0 | |
Secondary | 3-month survival rate | Death yes/no | 3 months | |
Secondary | Transfer to intensive care unit during hospitalization | Yes/no | 3 months | |
Secondary | Thrombotic complication during hospitalization | Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis) | 3 months | |
Secondary | Plasma concentrations of D-dimers | µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II) | Day 0 | |
Secondary | Plasma concentrations of soluble fibrin monomers | mg / L, measured by automated immunoagglutination (STA®-Liatest® FM) | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|